The search for improved antidepressant strategies: Is bigger better?

American Journal of Psychiatry

Volumn 168, Issue 7, 2011, Pages 664-666

  Coryel, William ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ESCITALOPRAM; FLUOXETINE; LITHIUM; MIRTAZAPINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

DRUG RESPONSE; EDITORIAL; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MELANCHOLIA; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 79960523604     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11030510     Document Type: Editorial

References (12)

1. Connolly KR, Thase ME: If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. D rugs 2011; 71:43-64
2. 3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519-1530
3. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231-1242
4. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ: Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243-1252
5. Blier P, Gobbi G, Turcotte JE, de Montigny C , Boucher N, Hebert C , Debonnel G: Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009; 19:457-465
6. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C , Bergeron R: Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167:281-288
7. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Shelton RC , Lesser IM, Kornstein SG, Wisniewski SR: Combining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011; 168:689-701
8. Khan A, Leventhal RM, Khan SR, Brown WA: Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22:40-45 (Pubitemid 34101291)
9. Zimmerman M, Black DW, Coryell W: Diagnostic criteria for melancholia: the comparative validity of DSM-III and DSM-III-R. Arch Gen Psychiatry 1989; 46:361-368 (Pubitemid 19111490)
10. Parker G, Roy K, Wilhelm K, Mitchell P: Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. J Clin Psychiatry 2001; 62:117-125 (Pubitemid 32199869)
11. Gormley N, O'Leary D, Costello F: First admissions for depression: is the 'no-treatment interval' a critical predictor of time to remission? J Affect Disord 1999; 54:49-54
12. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA: Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009; 166:42-49